Recruiting
Phase 1
Phase 2

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT03214562

Conditions

High Risk Myelodysplastic Syndrome

Recurrent Acute Myeloid Leukemia

Refractory Acute Myeloid Leukemia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Cytarabine

Filgrastim

Fludarabine

Idarubicin

Pegfilgrastim

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information